Inogen, Inc (NASDAQ:INGN) EVP Matt Scribner sold 2,500 shares of the company’s stock in a transaction on Friday, August 18th. The stock was sold at an average price of $92.45, for a total value of $231,125.00. Following the sale, the executive vice president now owns 6,964 shares of the company’s stock, valued at approximately $643,821.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Matt Scribner also recently made the following trade(s):

  • On Tuesday, July 18th, Matt Scribner sold 2,500 shares of Inogen stock. The stock was sold at an average price of $94.21, for a total value of $235,525.00.
  • On Friday, June 16th, Matt Scribner sold 2,500 shares of Inogen stock. The stock was sold at an average price of $91.54, for a total value of $228,850.00.

Inogen, Inc (NASDAQ INGN) opened at 94.01 on Thursday. The stock has a market cap of $1.95 billion, a PE ratio of 81.61 and a beta of 1.01. The firm has a 50-day moving average price of $94.31 and a 200 day moving average price of $84.02. Inogen, Inc has a 52-week low of $50.24 and a 52-week high of $98.33.

Inogen (NASDAQ:INGN) last issued its quarterly earnings results on Thursday, August 3rd. The medical technology company reported $0.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.10. The business had revenue of $64.10 million for the quarter, compared to the consensus estimate of $59.99 million. Inogen had a return on equity of 12.45% and a net margin of 10.36%. The business’s quarterly revenue was up 17.4% on a year-over-year basis. During the same period in the prior year, the firm posted $0.25 earnings per share. On average, analysts forecast that Inogen, Inc will post $1.21 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/24/matt-scribner-sells-2500-shares-of-inogen-inc-ingn-stock.html.

INGN has been the subject of several recent research reports. Zacks Investment Research upgraded Inogen from a “hold” rating to a “strong-buy” rating and set a $94.00 price target for the company in a report on Monday, May 15th. Needham & Company LLC decreased their price target on Inogen from $108.00 to $96.00 and set a “strong-buy” rating for the company in a report on Thursday, June 8th. J P Morgan Chase & Co upped their price target on Inogen to $102.00 and gave the stock an “overweight” rating in a report on Monday, June 26th. Stifel Nicolaus upped their price target on Inogen from $65.00 to $75.00 and gave the stock a “hold” rating in a report on Wednesday, May 10th. Finally, BidaskClub downgraded Inogen from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Three equities research analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $91.60.

Several institutional investors have recently modified their holdings of the company. Schroder Investment Management Group acquired a new position in shares of Inogen during the second quarter worth about $132,000. Ameritas Investment Partners Inc. acquired a new position in shares of Inogen during the first quarter worth about $109,000. Sei Investments Co. increased its position in shares of Inogen by 38.1% in the second quarter. Sei Investments Co. now owns 1,606 shares of the medical technology company’s stock worth $153,000 after buying an additional 443 shares during the last quarter. Victory Capital Management Inc. increased its position in shares of Inogen by 36.1% in the first quarter. Victory Capital Management Inc. now owns 1,729 shares of the medical technology company’s stock worth $134,000 after buying an additional 459 shares during the last quarter. Finally, State of Alaska Department of Revenue increased its position in shares of Inogen by 4.1% in the first quarter. State of Alaska Department of Revenue now owns 1,790 shares of the medical technology company’s stock worth $138,000 after buying an additional 70 shares during the last quarter.

Inogen Company Profile

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Insider Buying and Selling by Quarter for Inogen (NASDAQ:INGN)

Receive News & Stock Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related stocks with our FREE daily email newsletter.